Abstract:Male androgenetic alopecia is a common condition and represents a major concern for patients who experience this condition. While there are different treatments to stop hair loss and improve hair density, the 5-alpha reductase inhibitors have demonstrated to be effective in improving androgenetic alopecia in men and can maintain a positive response for many years. Oral finasteride 1 mg is a US FDA-approved option, but dutasteride 0.5 mg has been proven to induce better responses, especially in the frontal area. Both have been shown to be safe in clinical trials but there is widespread concern about sexual adverse effects among patients. The use of topical finasteride has increased during the last few years as a useful option to avoid systemic therapy. The efficacy of topical finasteride 0.25% daily has been demonstrated in clinical trials, with a less marked decrease in serum dihydrotestosterone levels than with oral intake. Mesotherapy with dutasteride has also become more widespread recently, although evidence of its effectiveness is limited to retrospective studies in real clinical practice. The use of oral minoxidil in androgenetic alopecia has not been approved by the FDA, however several clinical studies have shown that it is an effective treatment option. The initial dose recommended to treat male hair loss is 2.5 mg daily, although the dose is frequently increased to 5 mg daily. The main adverse effect of oral minoxidil is hypertrichosis, followed by dizziness or lower limb edema, which are much less common. Platelet-rich plasma is a non-pharmacological option to treat male androgenetic alopecia, with some clinical trials demonstrating an improvement in hair count after several months. Among the published studies, the main limitation to compare its efficacy is the heterogeneity of the procedure. The most frequent regimens propose treatment every 4 weeks for 3 months initially to assess the individual response. Another treatment alternative is the use of light devices with wavelengths of between 630 and 660 nm, known as low-level laser therapy. These devices can be used at home every day for 15–30 min. Their efficacy has been shown in a limited number of clinical trials; however, there is a lack of evidence about the efficacy of these devices compared with other medical options or as a complementary therapy in hair loss. The pipeline of potential new treatments for male androgenetic alopecia is strong. Pyrilutamide and GT20029 are being studied as topical antagonists of the androgen receptor, while cetirizine is another topical option with some initial promising results. Furthermore, according to isolated studies with heterogeneous treatment schemes, the use of botulinum toxin in the scalp might improve androgenetic alopecia, and lastly, scalp threading might increase the total hair count as growth factors are released during implantation.

Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review

Serum Levels of Androgen-Associated Hormones Are Correlated with Curative Effect in Androgenic Alopecia in Young Men

Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia

Topical dutasteride for androgenic alopecia: current state and prospects

What's New in Therapy for Male Androgenetic Alopecia?

Androgenetic Alopecia: Therapy Update

Androgenetic alopecia: An update

Phytotherapeutic Alternatives to the Use of Finasteride and Dutasteride as 5-Alpha Reductase Inhibitors in the Treatment of Androgenetic Alopecia: A Review

Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature

Androgenetic alopecia: an evidence-based treatment update

Dutasteride in the treatment of frontal fibrosing alopecia: Systematic review and meta‐analysis

A bibliometric analysis of alternative drug therapy options in the treatment of androgenetic alopecia

How to treat androgenetic alopecia – the most common form of hair loss. A review

Finasteride and androgenic alopecia; from therapeutic options to medical implications

The impact of monotherapies for male androgenetic alopecia: A network meta‐analysis study

Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics

Long‐term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5‐year data demonstrating clinical improvement with sustained efficacy

Comparative efficacy of various treatment regimens for androgenetic alopecia in men

Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia

The clinical research of finasteride and minoxidil for treating androgenic alopecia

Bioengineered Polyester Nanoparticles for the Synergistic Treatment of Androgenic Alopecia Via the Suppression of 5Α-Reductase and Knockdown of Androgen Receptor